Linden Thomas Advisory Services LLC Increases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Linden Thomas Advisory Services LLC boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 7,441 shares of the pharmaceutical company’s stock after acquiring an additional 644 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Vertex Pharmaceuticals were worth $2,996,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Northwest Investment Counselors LLC bought a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $25,000. Highline Wealth Partners LLC bought a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at $27,000. Dunhill Financial LLC lifted its position in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares in the last quarter. Legacy Investment Solutions LLC bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth $33,000. Finally, Truvestments Capital LLC purchased a new position in shares of Vertex Pharmaceuticals in the third quarter valued at $35,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $439.62 on Friday. The stock has a market capitalization of $113.22 billion, a P/E ratio of -220.91, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The business’s 50 day simple moving average is $435.36 and its two-hundred day simple moving average is $464.66.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.67 EPS. Analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on VRTX shares. Morgan Stanley increased their price objective on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Monday, January 13th. Scotiabank increased their target price on shares of Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a research note on Monday, December 23rd. Finally, Bank of America decreased their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a report on Thursday, December 19th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $494.84.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.